Consistent with BRCA2 and ATM showing association with disease severity, their effect sizes were larger in this aggressive prostate cancer versus controls analysis compared to the overall prostate cancer versus controls analysis (Fig. 2 and Table 2). This evidence concerns the gene BRCA2 and prostate carcinoma.